News

Advocates want NC legislature to consider rules around psychedelics for PTSD treatment

Advocates in North Carolina are urging lawmakers to support Senate Bill 568, which would create a task force to explore safe, regulated access to psychedelic-assisted therapy for PTSD—especially for veterans. While not legalizing psychedelics, the bill aims to prepare the state for future FDA approval through infrastructure planning and veteran-focused care.

RFK Jr. and other Trump officials embrace psychedelics after FDA setback

RFK Jr. and former Trump officials are backing psychedelic therapies like MDMA and ibogaine, pushing for FDA approval amid growing bipartisan interest. The article highlights veteran voices, including VETS' Marcus Capone, advocating for access despite safety concerns.

A New Hope for Healing: Psilocybin Clinical Trial Now Open to Veterans

Thanks to the recent passage of SB5263, Washington State is developing a robust legal framework for Washington residents over the age of 21 to access psilocybin services. With it comes a clinical trial designed specifically for U.S. veterans.

Advocate reacts to Texas governor signing psychedelic research bill into law

An advocate featured by KXAN celebrates Texas’s new legislation as a turning point—allocating $50 million in public funding for ibogaine clinical trials to address PTSD, addiction, and brain injury. She highlights the significance of this support for veterans and first responders.

Why Veterans With PTSD Are Turning to Psychedelics

Veterans are increasingly exploring psychedelic treatments—like ketamine, psilocybin, MDMA, and ibogaine—to heal from PTSD. These therapies tend to be used in guided, clinically-informed settings, with some programs even including spouses for shared healing. Although ibogaine remains illegal in the U.S., many veterans are traveling abroad, driven by promising early results

‘Psychedelics and the Texas Trip’ explores science & history behind state-funded research initiative

Texas recently approved $50 million in public funding, matched privately, to study ibogaine—a plant-derived psychedelic—as a potential treatment for PTSD, TBI, addiction, and related conditions. The initiative is facilitated through a public–private partnership and includes protections to ensure future therapy revenues fund veterans’ programs

Texas passes nation’s first ibogaine research funding bill; Colorado’s first Natural Medicine client; and Psilocybin’s effects wane a year after dosing

Texas is the first state to fund clinical trials of ibogaine, investing $50 million in public funds to explore its potential for treating PTSD, addiction, and TBI—with future revenues supporting veterans’ programs.

Texas governor signs bill allocating up to $100 million in funding for psychedelics research

Texas has passed a landmark bill dedicating up to $100 million—half from public funds—to study ibogaine for conditions like PTSD, TBI, and addiction. A portion of future revenue will directly support veterans’ programs, marking a major step toward expanding access to psychedelic-assisted therapies.

Los Angeles Times: California Veterans Fight to Fast-Track Study of ‘Lifesaving’ Psychedelic Therapy

Veterans Exploring Treatment Solutions (VETS) Takes Center Stage at Psychedelic Science 2025

Veterans Exploring Treatment Solutions (VETS) brought its mission to the forefront at Psychedelic Science 2025, spotlighting the urgent need for access, equity, and innovation in veteran mental health. From policy advocacy to powerful storytelling, VETS delivered a bold message: healing is a right—and veterans deserve the freedom to pursue it.